Keratonjunctivitis
Conditions
Brief summary
To explore the feasibility of combined topical corticosteroid and topical cyclosporine-A in COVID-19 patients with acute keratoconjunctivitis.
Detailed description
COVID-19 patients presenting with acute keratoconjunctivitis will be treated with Topical 1% prednisolone acetate fourTimes daily for 7 days as initial treatment, non-preserved artificial tears four times daily and cyclosporin A 0.5% four times daily . Twelve patients with COVID-19 Keratoconjunctivitis will be enrolled in this open-label study. Symptoms and findings of the patients before and after treatment were recorded.
Interventions
DRUGtopical steroids and cyclosporin-A
All patient will be treated with Topical 1% prednisolone acetate for 7 days as initial treatment +non-preserved artificial tears and cyclosporin A 0.5% four times daily .
Sponsors
Ministry of Health, Kuwait
Ameera Gamal Abdelhameed
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* COVID-19 Patients with keratoconjunctivitis
Exclusion criteria
* associated ocular pathology or disease * other causes of keratoconjunctivitis for example allergic or herpetic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Symptom improvement | 10-15 days | eye itching, foreign body sensation, tearing, redness in the eye and eyelid swelling |
| Signs improvement | 10-15 days | conjunctival injection, discharge, presence of superficial punctate keratitis (SPK), pseudomembranes on tarsal conjunctiva |
Countries
Kuwait
Contacts
Primary ContactAmeera Abdelhameed, MD
Outcome results
None listed